These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. N-terminal prohormone B-type natriuretic peptide and cardiovascular function in Africans and Caucasians: the SAfrEIC study. Kruger R; Schutte R; Huisman HW; Hindersson P; Olsen MH; Schutte AE Heart Lung Circ; 2012 Feb; 21(2):88-95. PubMed ID: 22119736 [TBL] [Abstract][Full Text] [Related]
29. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627 [TBL] [Abstract][Full Text] [Related]
30. The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine. Scharrenberg JS; Yagdiran A; Brinkmann J; Brune M; Siewe J; Jung N; Mahabir E J Orthop Surg Res; 2019 Nov; 14(1):367. PubMed ID: 31727136 [TBL] [Abstract][Full Text] [Related]
34. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment. Pawlak K; Buraczewska-Buczko A; Mysliwiec M; Pawlak D Am J Med Sci; 2010 Jan; 339(1):5-9. PubMed ID: 19926968 [TBL] [Abstract][Full Text] [Related]
35. Could soluble urokinase plasminogen receptor (suPAR) be used as a diagnostic biomarker for ventilator-associated pneumonia? Sunnetcioglu A; Sunnetcioglu M; Adıyaman F; Binici I; Soyoral L Clin Respir J; 2017 Nov; 11(6):925-930. PubMed ID: 26683264 [TBL] [Abstract][Full Text] [Related]
36. Serum Levels of Soluble Urokinase Plasminogen Activator Receptor in Infants with Late-onset Sepsis. Okulu E; Arsan S; Akin IM; Ates C; Alan S; Kilic A; Atasay B J Clin Lab Anal; 2015 Sep; 29(5):347-52. PubMed ID: 25043869 [TBL] [Abstract][Full Text] [Related]
37. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease. Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033 [TBL] [Abstract][Full Text] [Related]
38. Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema. Hilty MP; Zügel S; Schoeb M; Auinger K; Dehnert C; Maggiorini M Mediators Inflamm; 2016; 2016():1942460. PubMed ID: 27378823 [TBL] [Abstract][Full Text] [Related]
39. Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome. Hoenigl M; Raggam RB; Wagner J; Valentin T; Leitner E; Seeber K; Zollner-Schwetz I; Krammer W; Prüller F; Grisold AJ; Krause R Clin Biochem; 2013 Feb; 46(3):225-9. PubMed ID: 23159293 [TBL] [Abstract][Full Text] [Related]
40. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus. Toldi G; Szalay B; Bekő G; Bocskai M; Deák M; Kovács L; Vásárhelyi B; Balog A Biomarkers; 2012 Dec; 17(8):758-63. PubMed ID: 23033975 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]